OCALIVA® (obeticholic acid) is a prescription medicine used for the treatment of primary biliary cholangitis (PBC); its first approved treatment in nearly 20 years. Since this medicine is changing what's possible in PBC treatment, the brand had to encompass its revitalizing possibilities with a warm, energetic, and refreshing identity.
Our team worked on a range of design solutions for this brand, but my role included the development of the logo and identity as well as its accompanying print pieces.
Client: Intercept Pharmaceuticals • Agency: Cambridge BioMarketing
